Market Place
Sourcing Support
Iqirvo Data Shows Long Efficacy in PBC with Fatigue Improvement
15 Nov 2024 //
GLOBENEWSWIRE
GENFIT Announces Updates & Participation at Liver Meeting® 2024
13 Nov 2024 //
GLOBENEWSWIRE
UK MHRA Grants Approval For Ipsen’s Elafibranor Treatment
10 Oct 2024 //
PHARMABIZ
EU Approves Ipsen`s Iqirvo For Biliary Cholangitis
20 Sep 2024 //
GLOBENEWSWIRE
GENFIT Reports First Half-Year 2024 Financial Results
19 Sep 2024 //
GLOBENEWSWIRE
Ipsen Pharma`s Iqirvo (elafibranor) Receives Approval in Europe
19 Sep 2024 //
EMA
Ipsen Gets CHMP Nod For Iqirvo And Kayfanda In Rare Liver Diseases
26 Jul 2024 //
GLOBENEWSWIRE
EMA Committee Gives Positive Opinion On Ipsen`s Iqirvo For PBC
26 Jul 2024 //
GLOBENEWSWIRE
US FDA grants accelerated approval to Genfit and Ipsen`s liver disease drug
11 Jun 2024 //
REUTERS
Ipsen`s Iqirvo Receives Accelerated FDA Approval For Cholangitis Treatment
10 Jun 2024 //
GLOBENEWSWIRE
Ipsen: Long-Term Elafibranor Efficacy & QoL In PBC Patients
05 Jun 2024 //
GLOBENEWSWIRE
GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in PBC
08 Dec 2023 //
GLOBENEWSWIRE
Ipsen confirms U.S. FDA grants priority review for NDA for elafibranor
07 Dec 2023 //
GLOBENEWSWIRE
Results from Ipsen™s ELATIVE Phase III trial of elafibranor in PBC presented
13 Nov 2023 //
GLOBENEWSWIRE
Ipsen, Genfit`s elafibranor hits main goal of primary biliary cholangitis study
01 Jul 2023 //
PRESS RELEASE
Ipsen & GENFIT Announce +ve Results from Ph III ELATIVE® trial of elafibranor
30 Jun 2023 //
GLOBENEWSWIRE
Ipsen ends 2021 deal spree with $543M Genfit tie-up
18 Dec 2021 //
FIERCEBIOTECH
Ipsen places €480m bet on Genfit’s liver drug elafibranor
17 Dec 2021 //
PHARMAPHORUM
Ipsen, GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor in PBC
16 Dec 2021 //
BUSINESSWIRE
New Clinical Data on GENFIT’s Investigational Compound Elafibranor
02 Nov 2021 //
GLOBENEWSWIRE
GENFIT Announces 1st Patient 1st Visit for PhIII Study Evaluating Elafibranor
24 Sep 2020 //
GLOBENEWSWIRE
GenFit delivers latest NASH drug failure
12 May 2020 //
BIOPHA RMADIVE
Genfit`s NASH key phase 3 data delayed
21 Feb 2020 //
FIERCE BIOTECH
A PhII flop triggers an ugly rout for micro-cap biotech Aridis
04 Sep 2019 //
ENDPTS
Genfit founding CEO makes way for new blood
03 Sep 2019 //
FIERCE BIOTECH
Genfit`s elafibranor wins orphan status for primary biliary cholangitis
29 Jul 2019 //
ENDPTS
Genfit goes to China with a deal worth up to $228M for NASH drug
24 Jun 2019 //
ENDPTS
NASH contender CymaBay runs into trouble as mid-stage data disappoint
11 Jun 2019 //
ENDPTS
Genfit claims FDA breakthrough status for liver disease drug
19 Apr 2019 //
PMLIVE
Genfit bags FDA breakthrough tag en route to phase 3 in PBC
18 Apr 2019 //
FIERCE BIOTECH
UPDATED: France’s NASH contender Genfit leaps onto Nasdaq with $135M IPO
27 Mar 2019 //
ENDPTS
While we wait for NASH data, Genfit reports pos elafibranor data
06 Dec 2018 //
ENDPTS
